Théa is the leading independent European pharmaceutical group in ophthalmology.
Leader and pioneer in preservative-free treatments, Théa is the unique partner of the eye care professionals
for it has constantly been innovating to provide them and their patients with answers to unmet eye care needs. Today, Théa’s network includes 1,600 collaborators, and its products are available in 75 countries around the world through its 35 affiliates and partners. In 2021, Théa had global revenues of approximately $773 million. The independent and family-owned and run group, founded from a R&D start-up by Henri Chibret, has been chaired since 2008 by Jean-Frédéric Chibret.
